To minimize the side-effects associated with COX-1 inhibition, a selective COX-2 inhibitor is an attractive alternative, and in 2011, the anti-tumor effects of a selective COX-2 inhibitor, deracoxib, was used as a monotherapy for dogs with UC [109]. The gene discussed is PTGER2; the disease is neoplasm.